Frataxin

"FXN" redirects here. For the railway station, see Foxton railway station.

FXN
Available structures PDB Ortholog search: PDBe RCSB List of PDB id codes 1EKG, 1LY7, 3S4M, 3S5D, 3S5E, 3S5F, 3T3J, 3T3K, 3T3L, 3T3T, 3T3X
Identifiers
Aliases	FXN, CyaY, FA, FARR, FRDA, X25, frataxin
External IDs	OMIM: 606829; MGI: 1096879; HomoloGene: 47908; GeneCards: FXN; OMA:FXN - orthologs
Gene location (Human) Chr. Chromosome 9 (human) Band 9q21.11 Start 69,035,751 bp End 69,079,076 bp
Gene location (Mouse) Chr. Chromosome 19 (mouse) Band 19|19 B Start 24,238,817 bp End 24,257,969 bp
RNA expression pattern Bgee Human Mouse (ortholog) Top expressed in right lobe of liver apex of heart left ventricle right adrenal gland right adrenal cortex muscle of thigh left adrenal gland left adrenal cortex gastrocnemius muscle right auricle Top expressed in bone marrow myocardium of ventricle cardiac muscles proximal tubule cardiac muscle tissue of left ventricle right kidney epithelium of small intestine intestinal villus quadriceps femoris muscle Ileal epithelium More reference expression data BioGPS More reference expression data
Gene ontology Molecular function protein binding iron chaperone activity 2 iron, 2 sulfur cluster binding oxidoreductase activity ferrous iron binding metal ion binding ferric iron binding ferroxidase activity Cellular component cytoplasm cytosol mitochondrial matrix mitochondrion L-cysteine desulfurase complex Biological process regulation of ferrochelatase activity positive regulation of cell population proliferation response to iron ion iron-sulfur cluster assembly ion transport positive regulation of aconitate hydratase activity positive regulation of cell growth cellular response to hydrogen peroxide negative regulation of release of cytochrome c from mitochondria positive regulation of succinate dehydrogenase activity protein autoprocessing negative regulation of apoptotic process small molecule metabolic process iron ion homeostasis iron incorporation into metallo-sulfur cluster cellular iron ion homeostasis heme biosynthetic process positive regulation of lyase activity positive regulation of catalytic activity oxidative phosphorylation mitochondrion organization adult walking behavior aerobic respiration embryo development ending in birth or egg hatching proprioception negative regulation of multicellular organism growth negative regulation of organ growth Sources:Amigo / QuickGO
Orthologs Species Human Mouse Entrez 2395 14297 Ensembl ENSG00000165060 ENSMUSG00000059363 UniProt Q16595 O35943 RefSeq (mRNA) NM_181425 NM_000144 NM_001161706 NM_008044 RefSeq (protein) NP_000135 NP_852090 NP_032070 Location (UCSC) Chr 9: 69.04 – 69.08 Mb Chr 19: 24.24 – 24.26 Mb PubMed search
Wikidata
View/Edit Human View/Edit Mouse

Frataxin is a protein that in humans is encoded by the FXN gene.

It is located in the mitochondrion and Frataxin mRNA is mostly expressed in tissues with a high metabolic rate. The function of frataxin is not clear but it is involved in assembly of iron-sulfur clusters. It has been proposed to act as either an iron chaperone or an iron storage protein. Reduced expression of frataxin is the cause of Friedreich's ataxia.

Structure

X-ray crystallography has shown that human frataxin consists of a β-sheet that supports a pair of parallel α-helices, forming a compact αβ sandwich. Frataxin homologues in other species are similar, sharing the same core structure. However, the frataxin tail sequences, extending from the end of one helix, diverge in sequence and differ in length. Human frataxin has a longer tail sequence than frataxin found in bacteria or yeast. It is hypothesized that the purpose of the tail is to stabilize the protein.

Like most mitochondrial proteins, frataxin is synthesized in cytoplasmic ribosomes as large precursor molecules with mitochondrial targeting sequences. Upon entry into mitochondria, the molecules are broken down by a proteolytic reaction to yield mature frataxin.

Function

Frataxin is localized to the mitochondrion. The function of frataxin is not entirely clear, but it seems to be involved in assembly of iron-sulfur clusters. It has been proposed to act as either an iron chaperone or an iron storage protein.

Frataxin mRNA is predominantly expressed in tissues with a high metabolic rate (including liver, kidney, brown fat and heart). Mouse and yeast frataxin homologues contain a potential N-terminal mitochondrial targeting sequence, and human frataxin has been observed to co-localise with a mitochondrial protein. Furthermore, disruption of the yeast gene has been shown to result in mitochondrial dysfunction. Friedreich's ataxia is thus believed to be a mitochondrial disease caused by a mutation in the nuclear genome (specifically, expansion of an intronic GAA triplet repeat in the FXN gene, which encodes the protein frataxin.).

Clinical significance

Reduced expression of frataxin is the cause of Friedreich's ataxia (FRDA), a neurodegenerative disease. The reduction in frataxin gene expression may be attributable from either the silencing of transcription of the frataxin gene because of epigenetic modifications in the chromosomal entity or from the inability of splicing the expanded GAA repeats in the first intron of the pre-mRNA as seen in bacteria and Human cells or both. The expansion of intronic trinucleotide repeat GAA results in Friedreich's ataxia. This expanded repeat causes R-loop formation, and using a repeat-targeted oligonucleotide to disrupt the R-loop can reactivate frataxin expression.

96% of FRDA patients have a GAA trinucleotide repeat expansion in intron 1 of both alleles of their FXN gene. Overall, this leads to a decrease in frataxin mRNA synthesis and a decrease (but not absence) in frataxin protein in people with FRDA. (A subset of FRDA patients have GAA expansion in one chromosome and a point mutation in the FXN exon in the other chromosome.) In the typical case, the length of the allele with the shorter GAA expansion inversely correlates with frataxin levels. FRDA patients’ peripheral tissues typically have less than 10% of the frataxin levels exhibited by unaffected people. Lower levels of frataxin result in earlier disease onset and faster progression.

FRDA is characterized by ataxia, sensory loss, and cardiomyopathy. The reason frataxin deficiency causes these symptoms is not entirely clear. On a cellular level, it is linked to iron accumulation in the mitochondria and increased oxidant sensitivity. For reasons that are not well understood, this primarily affects the tissue of the dorsal root ganglia, cerebellum, and heart muscle.

Animal studies

In mice, complete inactivation of the FXN homolog (Frda) is lethal in the early embryonic stage. Although nearly all organisms express a frataxin homologue, the GAA repeat in intron 1 only exists in humans and other primates, so the mutation that causes FDRA can't occur naturally in other animals. Scientists have developed several options to model this disease in mice. One approach is to silence frataxin expression in just one specific tissue type of interest: the heart (mice modified this way are called MCK), all neurons (NSE), or just the spinal cord and cerebellum (PRP). Another approach involves inserting a GAA expansion into the first intron of the mouse FXN gene, which should inhibit frataxin production, just like in humans. Mice that are homozygous for this modified gene are called KIKI (knock-in knock-in), and the compound heterozygotes formed by crossing KIKI mice with frataxin knockout mice are called KIKO (knock-in knock-out). However, even KIKO mice still express 25-36% of the normal frataxin level, and show very mild symptoms. The final approach involves creating transgenic mice with a GAA-expanded version of the human frataxin gene. These mice are called YG22R (one GAA sequence of 190 repeats) and YG8R (two GAA sequences of 90 and 190 repeats). These mice show symptoms similar to human patients.

An overexpression of frataxin in Drosophila has shown an increase in antioxidant capability, resistance to oxidative stress insults and longevity, supporting the theory that the role of frataxin is to protect the mitochondria from oxidative stress and the ensuing cellular damage.

Fibroblasts from a mouse model of FRDA and FRDA patient fibroblasts show increased levels of DNA double-strand breaks. A lentivirus gene delivery system was used to deliver the frataxin gene to the FRDA mouse model and human patient cells, and this resulted in long-term restored expression of frataxin mRNA and frataxin protein. This restored expression of the frataxin gene was accompanied by a substantial reduction in the number of DNA double-strand breaks. The impaired frataxin in FRDA cells appears to cause reduced capacity for repair of DNA damage and this may contribute to neurodegeneration.

Interactions

Frataxin has been shown to biologically interact with the enzyme PMPCB.

Further reading

• Thierbach R, Drewes G, Fusser M, Voigt A, Kuhlow D, Blume U, Schulz TJ, Reiche C, Glatt H, Epe B, Steinberg P, Ristow M (Nov 2010). "The Friedreich's ataxia protein frataxin modulates DNA base excision repair in prokaryotes and mammals". The Biochemical Journal. 432 (1): 165–72. doi:10.1042/BJ20101116. PMC 2976068. PMID 20819074.
• Montermini L, Rodius F, Pianese L, Moltò MD, Cossée M, Campuzano V, Cavalcanti F, Monticelli A, Palau F, Gyapay G (Nov 1995). "The Friedreich ataxia critical region spans a 150-kb interval on chromosome 9q13". American Journal of Human Genetics. 57 (5): 1061–7. PMC 1801369. PMID 7485155.
• Bidichandani SI, Ashizawa T, Patel PI (May 1997). "Atypical Friedreich ataxia caused by compound heterozygosity for a novel missense mutation and the GAA triplet-repeat expansion". American Journal of Human Genetics. 60 (5): 1251–6. PMC 1712428. PMID 9150176.
• Babcock M, de Silva D, Oaks R, Davis-Kaplan S, Jiralerspong S, Montermini L, Pandolfo M, Kaplan J (Jun 1997). "Regulation of mitochondrial iron accumulation by Yfh1p, a putative homolog of frataxin". Science. 276 (5319): 1709–12. doi:10.1126/science.276.5319.1709. PMID 9180083.
• Koutnikova H, Campuzano V, Foury F, Dollé P, Cazzalini O, Koenig M (Aug 1997). "Studies of human, mouse and yeast homologues indicate a mitochondrial function for frataxin". Nature Genetics. 16 (4): 345–51. doi:10.1038/ng0897-345. PMID 9241270. S2CID 5883249.
• Wilson RB, Roof DM (Aug 1997). "Respiratory deficiency due to loss of mitochondrial DNA in yeast lacking the frataxin homologue". Nature Genetics. 16 (4): 352–7. doi:10.1038/ng0897-352. PMID 9241271. S2CID 22652291.
• Campuzano V, Montermini L, Lutz Y, Cova L, Hindelang C, Jiralerspong S, Trottier Y, Kish SJ, Faucheux B, Trouillas P, Authier FJ, Dürr A, Mandel JL, Vescovi A, Pandolfo M, Koenig M (Oct 1997). "Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes". Human Molecular Genetics. 6 (11): 1771–80. doi:10.1093/hmg/6.11.1771. PMID 9302253.
• Rötig A, de Lonlay P, Chretien D, Foury F, Koenig M, Sidi D, Munnich A, Rustin P (Oct 1997). "Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia". Nature Genetics. 17 (2): 215–7. doi:10.1038/ng1097-215. PMID 9326946. S2CID 23151137.
• Jiralerspong S, Liu Y, Montermini L, Stifani S, Pandolfo M (1997). "Frataxin shows developmentally regulated tissue-specific expression in the mouse embryo". Neurobiology of Disease. 4 (2): 103–13. doi:10.1006/nbdi.1997.0139. PMID 9331900. S2CID 6520439.
• Koutnikova H, Campuzano V, Koenig M (Sep 1998). "Maturation of wild-type and mutated frataxin by the mitochondrial processing peptidase". Human Molecular Genetics. 7 (9): 1485–9. doi:10.1093/hmg/7.9.1485. PMID 9700204.
• Zühlke C, Laccone F, Cossée M, Kohlschütter A, Koenig M, Schwinger E (Jul 1998). "Mutation of the start codon in the FRDA1 gene: linkage analysis of three pedigrees with the ATG to ATT transversion points to a unique common ancestor". Human Genetics. 103 (1): 102–5. doi:10.1007/s004390050791. PMID 9737785. S2CID 26999143.
• Bartolo C, Mendell JR, Prior TW (Oct 1998). "Identification of a missense mutation in a Friedreich's ataxia patient: implications for diagnosis and carrier studies". American Journal of Medical Genetics. 79 (5): 396–9. doi:10.1002/(SICI)1096-8628(19981012)79:5<396::AID-AJMG13>3.0.CO;2-M. PMID 9779809.
• Cossée M, Dürr A, Schmitt M, Dahl N, Trouillas P, Allinson P, Kostrzewa M, Nivelon-Chevallier A, Gustavson KH, Kohlschütter A, Müller U, Mandel JL, Brice A, Koenig M, Cavalcanti F, Tammaro A, De Michele G, Filla A, Cocozza S, Labuda M, Montermini L, Poirier J, Pandolfo M (Feb 1999). "Friedreich's ataxia: point mutations and clinical presentation of compound heterozygotes". Annals of Neurology. 45 (2): 200–6. doi:10.1002/1531-8249(199902)45:2<200::AID-ANA10>3.0.CO;2-U. PMID 9989622. S2CID 24885238.
• Coppola G, De Michele G, Cavalcanti F, Pianese L, Perretti A, Santoro L, Vita G, Toscano A, Amboni M, Grimaldi G, Salvatore E, Caruso G, Filla A (May 1999). "Why do some Friedreich's ataxia patients retain tendon reflexes? A clinical, neurophysiological and molecular study". Journal of Neurology. 246 (5): 353–7. doi:10.1007/s004150050362. PMID 10399865. S2CID 7367457.
• Branda SS, Cavadini P, Adamec J, Kalousek F, Taroni F, Isaya G (Aug 1999). "Yeast and human frataxin are processed to mature form in two sequential steps by the mitochondrial processing peptidase". The Journal of Biological Chemistry. 274 (32): 22763–9. doi:10.1074/jbc.274.32.22763. PMID 10428860.
• Gordon DM, Shi Q, Dancis A, Pain D (Nov 1999). "Maturation of frataxin within mammalian and yeast mitochondria: one-step processing by matrix processing peptidase". Human Molecular Genetics. 8 (12): 2255–62. doi:10.1093/hmg/8.12.2255. PMID 10545606.
• Forrest SM, Knight M, Delatycki MB, Paris D, Williamson R, King J, Yeung L, Nassif N, Nicholson GA (Aug 1998). "The correlation of clinical phenotype in Friedreich ataxia with the site of point mutations in the FRDA gene". Neurogenetics. 1 (4): 253–7. doi:10.1007/s100480050037. PMID 10732799. S2CID 7463903.
• Al-Mahdawi S, Pook M, Chamberlain S (Jul 2000). "A novel missense mutation (L198R) in the Friedreich's ataxia gene". Human Mutation. 16 (1): 95. doi:10.1002/1098-1004(200007)16:1<95::AID-HUMU29>3.0.CO;2-E. PMID 10874325. S2CID 26295274.

External links

• GeneReviews/NCBI/NIH/UW entry on Friedreich Ataxia
• frataxin at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
• Overview of all the structural information available in the PDB for UniProt: Q16595 (Frataxin, mitochondrial) at the PDBe-KB.